CLINICAL TRIAL collaboration AGREEMENTClinical Trial Collaboration Agreement • September 9th, 2014 • Advaxis, Inc. • Pharmaceutical preparations • Delaware
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • November 4th, 2016 • Nektar Therapeutics • Pharmaceutical preparations • New York
This Clinical Trial Collaboration Agreement (the “Agreement”) is made and entered into effective as of September 21, 2016 (the “Effective Date”) by and between Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (“Nektar”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Nektar and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • November 9th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of September 21, 2018 (the “Effective Date”) by and between BioXcel Therapeutics, a Delaware corporation, headquartered at 780 East Main Street, Branford, CT 06405 (“BioXcel”), and Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (“Nektar”). BioXcel and Nektar may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • March 18th, 2015 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • February 28th, 2022 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations
This CLINICAL TRIAL COLLABORATION AGREEMENT (this “Agreement”), dated as of October 13, 2021 (the “Effective Date”), is by and between EQRx, Inc., a Delaware corporation having a place of business at 50 Hampshire Street, Cambridge, MA 02139 (“EQRx”), and Turning Point Therapeutics, Inc., a Delaware corporation having a place of business at 10628 Science Center Drive, Suite 200, San Diego, CA 92121 (“TPT”). EQRx and TPT are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
